

Biocept Inc

08:59 14 Feb 2020

Biocept promotes Cory Dunn to senior vice president of commercial operations

Biocept Inc (NASDAQ:BIOC), a provider of liquid biopsy tests, has promoted Cory Dunn to senior vice president of commercial operations.

Dunn succeeds Edwin Hendrick, who resigned to pursue other endeavors, the San Diego-based company said in a statement Friday.

She has served as Biocept's vice president of commercial operations since October 2018. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (now Decipher Biosciences), PLUS Diagnostics (now Inform Diagnostics) and Genoptix.

READ: Biocept partners with California physician association to provide cancer testing

Dunn holds an MA in education from Stanford University, and MS in Biology and BS in Biochemistry and Cell Biology from the University of California, San Diego.

Her promotion comes as Biocept advances the usage of its flagship Target Selector technology platform, which collects and analyzes molecular markers linked to tumors in circulating tumor cells as well as plasma to identify cancer mutations. The assays detect lung, breast, gastric, colorectal and prostate cancers as well as melanoma.

"Cory has done a fantastic job over the past several years in expanding our Target Selector strategy into urology and oncology, and we are delighted that she will head our commercial operations," said CEO Michael Nall.

"The entire team is united behind Cory's sales and marketing leadership and we look forward to providing updates on our commercial progress. I want to thank Edwin Hendrick for his leadership and dedication to Biocept and we wish him all the best in his future endeavors."

Dunn added: "I look forward to taking on this new challenge and am enthusiastic about working with the commercial team to expand Biocept's reach and the universe of patients who can benefit from our Target Selector testing."

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: 0.5398

Market Cap: \$74.73 m

1 Year Share Price Graph



June 2019 November 2019 June 2020

Share Information

Code: BIOC

Listing: NASDAQ

52 week	High	Low
	1.24	0.2118

Sector: Medical technology & services

Website: biocept.com

Company Synopsis:

Biocept, Inc. is a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both CTCs and in plasma (ctDNA).

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts

journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).